Dr. Tak has received consulting fees from Abbott, Centocor, Schering-Plough, and Wyeth (less than $10,000 each).
Article first published online: 28 JAN 2011
Copyright © 2011 by the American College of Rheumatology
Arthritis & Rheumatism
Volume 63, Issue 2, pages 359–364, February 2011
How to Cite
Klaasen, R., Wijbrandts, C. A., Gerlag, D. M. and Tak, P. P. (2011), Body mass index and clinical response to infliximab in rheumatoid arthritis. Arthritis & Rheumatism, 63: 359–364. doi: 10.1002/art.30136
This publication reflects only the authors' views; the European Community is not liable for any use that may be made of the information herein.
- Issue published online: 28 JAN 2011
- Article first published online: 28 JAN 2011
- Accepted manuscript online: 8 NOV 2010 11:37AM EST
- Manuscript Accepted: 28 OCT 2010
- Manuscript Received: 12 JUN 2010
- Health Care Efficiency Research Programme grant from The Netherlands Organization for Health Research and Development (ZonMw) in assignment of The Netherlands Organization for Scientific Research. Grant Number: 945-02-029
- Dutch Arthritis Association
- European Union Sixth Framework Programme (project AutoCure)
Adipose tissue has immunomodulating effects in rheumatoid arthritis (RA), although the exact role is, at present, unclear. The purpose of this study was to determine whether body mass index (BMI) affects response to infliximab in RA patients investigated prospectively.
In 89 patients with active RA, the BMI was calculated before initiation of infliximab treatment (3 mg/kg intravenously). After 16 weeks of treatment, changes in disease activity were assessed with the Disease Activity Score in 28 joints (DAS28).
The mean ± SD BMI was 26 ± 5 kg/m2 (range 17–42). The BMI correlated positively with the DAS28 at baseline (r = 0.34, P = 0.001). Since selection of study patients according to DAS28 values could influence the clinical response to tumor necrosis factor (TNF) blockade due to regression to the mean because the clinical response is itself based on the change in the DAS28 values, analysis of covariance was used to correct for the baseline DAS28. A highly significant, negative association between the BMI and the absolute decrease in the DAS28 after 16 weeks (P = 0.001) was found also when adjusted for anti–citrullinated protein antibodies.
Although the infliximab dosage is based on body weight, RA patients with a high BMI responded less well to infliximab, a finding that held true when adjusted for the baseline DAS28 or anti–citrullinated protein antibody status. These results support the notion that adipose tissue may be involved in the pathophysiology of RA and could have implications for other immune-mediated inflammatory conditions treated with TNF antagonists.